{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:00:45Z","timestamp":1783472445824,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.08.052","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:21:01Z","timestamp":1535998861000},"page":"6170-6182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo"],"prefix":"10.1016","volume":"36","author":[{"given":"Didier","family":"Nzolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Engo Biongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kuemmerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Lusakibanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ntamabyaliro","family":"Nsengi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestin","family":"Nsibu Ndosimao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Tona Lutete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Van Geertruyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.08.052_b0005","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1016\/j.vaccine.2010.10.015","article-title":"Is it time for a new yellow fever vaccine?","volume":"28","author":"Hayes","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.052_b0010","first-page":"1","article-title":"Fever vaccine recommendations of the advisory committee","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2018.08.052_b0015","unstructured":"Vainio J, Cutts F. Yellow fever, vol. 11; 1998."},{"key":"10.1016\/j.vaccine.2018.08.052_b0020","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4269\/ajtmh.1980.29.912","article-title":"Yellow fever in the Gambia, 1978\u20131979: epidemiologic aspects with observations on the occurrence of Orungo virus infections","volume":"29","author":"Monath","year":"1980","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.08.052_b0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0035-9203(89)90518-X","article-title":"Urban yellow fever epidemic in western Nigeria, 1987","volume":"83","author":"Nasidi","year":"1989","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.08.052_b0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/rmv.584","article-title":"The enigma of yellow fever in East Africa","volume":"18","author":"Ellis","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2018.08.052_b0035","unstructured":"European Centre for Disease Prevention and Control. Rapid Risk Assessment. Outbreaks of yellow fever in Angola. Democratic Republic of Congo and Uganda Second update, 13 July 2016; 2016. p. 1\u201310. <https:\/\/ecdc.europa.eu\/en\/publications-data\/rapid-risk-assessment-outbreaks-yellow-fever-angola-democratic-republic-congo-0> [accessed February 20, 2018]."},{"key":"10.1016\/j.vaccine.2018.08.052_b0040","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/S0140-6736(16)30835-2","article-title":"Yellow fever continues to spread in Angola","volume":"387","author":"Green","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.08.052_b0045","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/S0140-6736(16)31838-4","article-title":"Fractional dosing of yellow fever vaccine to extend supply: a modeling study","volume":"388","author":"Wu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.08.052_b0050","unstructured":"SAGE-WHO. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response WHO Secretariat information paper; 2016. p. 39. doi:WHO\/YF\/SAGE\/16.1."},{"key":"10.1016\/j.vaccine.2018.08.052_b0055","unstructured":"World Health Organization. Yellow fever mass vaccination campaign using fractional dose in Kinshasa. DRC; 2016. p. 1\u20135. <http:\/\/www.who.int\/immunization\/sage\/meetings\/2016\/october\/4_Yellow_fever_mass_vaccination_campaign_using_fractional_dose_in_Kinshasa.pdf> [accessed February 28, 2018]."},{"key":"10.1016\/j.vaccine.2018.08.052_b0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of fractional-dose vaccine during a yellow fever outbreak \u2014 preliminary report","author":"Ahuka-Mundeke","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.08.052_b0065","doi-asserted-by":"crossref","DOI":"10.1179\/2047773213Y.0000000113","article-title":"Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary results","volume":"107","author":"Nzolo","year":"2013","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2018.08.052_b0070","doi-asserted-by":"crossref","DOI":"10.1179\/2047773214Y.0000000151","article-title":"Assessment of attitudes towards adverse events following immunization with oral poliovirus vaccine: a pilot study among high school students of Kinshasa, the Democratic Republic of Congo","volume":"108","author":"Kinuani","year":"2014","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2018.08.052_b0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40801-017-0110-0","article-title":"Central and peripheral nervous system disorders following ivermectin mass administration : a descriptive study based on the Democratic Republic of Congo pharmacovigilance system","volume":"4","author":"Nzolo","year":"2017","journal-title":"Drugs Real World Outcom"},{"key":"10.1016\/j.vaccine.2018.08.052_b0080","unstructured":"nzolo, didier. Most reported adverse events with fractional dose of 17DD Yellow fever vaccine. Mendeley Data; 2018. https:\/\/doi.org\/10.17632\/gv5p7vb6ng.1."},{"key":"10.1016\/j.vaccine.2018.08.052_b0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jtm.12070","article-title":"Safety of the yellow fever vaccine: a retrospective study","volume":"20","author":"Nordin","year":"2013","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.08.052_b0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.08.052_b0095","unstructured":"PRODUCT INFORMATION STAMARIL, powder and solvent for suspension for injection in multidose container Yellow fever vaccine (Live); 2013. p. 1\u201319. <http:\/\/www.travax.nhs.uk\/media\/923854\/stamaril_multi-dose_product_information.pdf> [accessed February 19, 2018]."},{"key":"10.1016\/j.vaccine.2018.08.052_b0100","unstructured":"Pasteur S. Yellow Fever Vaccine YF-VAX\u00ae. Sanofi Pasteur LE6103-LE6104; 2016. p. 1\u201326. <vaccines.procon.org\/sourcefiles\/YF-Vax-Package-Insert-2016.pdf> [accessed February 19, 2018]."},{"key":"10.1016\/j.vaccine.2018.08.052_b0105","first-page":"9","article-title":"Review of adverse events reported following use of yellow fever vaccine\u2013Canada, 1987\u20132000","volume":"28","author":"Choudri","year":"2002","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.vaccine.2018.08.052_b0110","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.vaccine.2014.01.015","article-title":"Yellow fever vaccine-associated adverse events following extensive immunization in Argentina","volume":"32","author":"Biscayart","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.052_b0115","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.052_b0120","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.vaccine.2008.04.054","article-title":"Sexual dimorphism of humoral immunity with human vaccines","volume":"26","author":"Cook","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.052_b0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/trstmh\/tru167","article-title":"Sex-based differences in immune function and responses to vaccination","volume":"109","author":"Kleina","year":"2015","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.08.052_b0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.medmal.2008.06.031","article-title":"Vaccination contre la fi\u00e8vre jaune en dehors des sujets immunocomp\u00e9tents. TT - [yellow fever vaccination in non-immunocompetent patients]","volume":"38","author":"Bruyand","year":"2008","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.vaccine.2018.08.052_b0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.08.052_b0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2018.08.052_b0145","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.08.052_b0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.vaccine.2004.05.018","article-title":"Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast","volume":"23","author":"Fitzner","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.052_b0155","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18311812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18311812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T11:41:40Z","timestamp":1536925300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18311812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":31,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X18311812"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}